A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models

The authors investigate the efficacy of a novel ribonuclease-targeting chimera (MYC-RiboTAC) designed to degrade MYC mRNA in multiple myeloma (MM) cells, addressing the challenge of targeting the MYC oncogene. Their findings demonstrate that MYC-RiboTAC effectively reduces MYC expression, inhibits MYC-driven transcriptional programs, and shows potent anti-MM activity, particularly in combination with existing therapies, suggesting its potential as a precision treatment for cancers driven by "undruggable" proteins like MYC.